这是演示店铺，请务下单付款，避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验，建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?)，感谢您选择我们！

首页   400-620-6333
提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.
  • 英文站
  • 登录
切换导航
我的购物车
搜索
搜索444
高级搜索
菜单
登录
྾

Nivolumab (anti-PD-1)

功能和特点
  • 规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
  • 应用: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • 反应种属: Cynomolgus,Human
  • 亚型: Human IgG4SP
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
N411994-1mg (试用装)
申请此免费试用装（?）
作为尊贵的客户，您每年可免费申请一次试用装产品，尽享探索与享受！
 		1mg 现货 Stock Image
N411994-5mg
 5mg 现货 Stock Image
N411994-10mg
 10mg 现货 Stock Image
大包装询价 添加到收藏夹 比较  SDS中文版  DATASHEET
查看相关系列
programmed cell death 1 (CD279) Antibody
main product photo

基本信息

产品名称 Nivolumab (anti-PD-1)
别名 纳武单抗; Nivolumab (anti-PD-1); Recombinant Nivolumab Antibody; BMS-936558; ONO-4538; MDX-1106; Opdivo; Anti-PDCD1 / PD-1 / CD279 Reference Antibody (nivolumab); CD279 antibody; CD279 antigen antibody; HPD 1 antibody; HPD l antibody; HPD-1 antibody; HSLE1 a
英文别名 Nivolumab (anti-PD-1); Recombinant Nivolumab Antibody; BMS-936558; ONO-4538; MDX-1106; Opdivo; Anti-PDCD1 / PD-1 / CD279 Reference Antibody (nivolumab); CD279 antibody; CD279 antigen antibody; HPD 1 antibody; HPD l antibody; HPD-1 antibody; HSLE1 antibod
规格或纯度 Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性 PDCD1/PD-1/CD279
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属 Cynomolgus,Human

产品属性

抗体类型 Primary antibody
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 Kappa
SDS-PAGE 26.4 kDa (Light Chain) & 53.3 kDa (Heavy Chain), under reducing conditions; 178.6 kDa, under non-reducing conditions.
纯化方法 Protein A purified
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 Lot by Lot
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息 946414-94-4

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

图片

Nivolumab (anti-PD-1) (N411994) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Nivolumab (anti-PD-1) (N411994). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Nivolumab (anti-PD-1) (N411994) - SEC
The purity of Nivolumab (anti-PD-1) (N411994) is more than 95% verified by HPLC.

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
查看全部
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Janakiram M, Abadi YM, Sparano JA, Zang X.  (2012)  T cell coinhibition and immunotherapy in human breast cancer..  Discov Med,  14  (77):  (229-36).  [PMID:23114578]
2. Greaves P, Gribben JG.  (2013)  The role of B7 family molecules in hematologic malignancy..  Blood,  121  (5):  (734-44).  [PMID:23223433]
3. Tang PA, Heng DY.  (2013)  Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer..  Curr Oncol Rep,  15  (2):  (98-104).  [PMID:23263823]
4. Hamid O, Carvajal RD.  (2013)  Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy..  Expert Opin Biol Ther,  13  (6):  (847-61).  [PMID:23421934]
5. Intlekofer AM, Thompson CB.  (2013)  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy..  J Leukoc Biol,  94  (1):  (25-39).  [PMID:23625198]
6. Callahan MK, Wolchok JD.  (2013)  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy..  J Leukoc Biol,  94  (1):  (41-53).  [PMID:23667165]
7. O'Sullivan Coyne G, Madan RA, Gulley JL.  (2014)  Nivolumab: promising survival signal coupled with limited toxicity raises expectations..  J Clin Oncol,  32  (10):  (986-8).  [PMID:24590655]
8. Luke JJ, Ott PA.  (2015)  PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma..  Oncotarget,  6  (6):  (3479-92).  [PMID:25682878]
9. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al..  (2015)  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma..  N Engl J Med,  372  (21):  (2006-17).  [PMID:25891304]
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al..  (2015)  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma..  N Engl J Med,  373  (1):  (23-34).  [PMID:26027431]
11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  (2015)  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma..  N Engl J Med,  373  (19):  (1803-13).  [PMID:26406148]
12. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al..  (2018)  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma..  N Engl J Med,  378  (14):  (1277-1290).  [PMID:29562145]
13. Pardoll DM.  (2012)  The blockade of immune checkpoints in cancer immunotherapy..  Nat Rev Cancer,  12  (4):  (252-64).  [PMID:22437870]
14. Topalian SL, Drake CG, Pardoll DM.  (2015)  Immune checkpoint blockade: a common denominator approach to cancer therapy..  Cancer Cell,  27  (4):  (450-61).  [PMID:25858804]

计算器

上海阿拉丁生化科技股份有限公司
销售条款及条件         隐私政策
© 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
沪公网安备 31012002004058号 沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

上海工商 危险品化学品经营许可证（带存储）营业执照(三证合一)